SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2928533142> ?p ?o ?g. }

Showing items 1 to 100 of ±117 with 100 items per page.

W2928533142 endingPage "66" @default.
W2928533142 startingPage "58" @default.
W2928533142 abstract "Novel therapies to override chemo-radiation resistance in prostate cancer (PCa) are needed. Prostate cancer sphere-forming cells (PCSCs) (also termed prostate cancer stem-like cells) likely participate in tumor progression and recurrence, and they are important therapeutic targets. We established PCSC-enriched spheres by culturing human (DU145) and murine (TRAMP-C2) PCa cells in growth factor-defined serum-free medium, and we characterized stem-like properties of clonogenicity and tumorigenicity. The efficacy of two different oncolytic herpes simplex viruses (oHSVs) (G47Δ and MG18L) in PCSCs was tested alone and in combination with radiation; chemotherapy; and inhibitors of phosphoinositide 3-kinase (PI3K), Wnt, and NOTCH in vitro; and, G47Δ was tested with the PI3K inhibitor BKM120 in a PCSC-derived tumor model in vivo. PCSCs were more tumorigenic than serum-cultured parental cells. Human and murine PCSCs were sensitive to oHSV and BKM120 killing in vitro, while the combination was synergistic. oHSV combined with radiation, docetaxel, Wnt, or NOTCH inhibitors was not. In athymic mice bearing DU145 PCSC-derived tumors, the combination of intra-tumoral G47Δ and systemic BKM120 induced complete regression of tumors in 2 of 7 animals, and it exhibited superior anti-tumor activity compared to either monotherapy alone, with no detectable toxicity. oHSV synergizes with BKM120 in killing PCSCs in vitro, and the combination markedly inhibits tumor growth, even inducing regression in vivo. Novel therapies to override chemo-radiation resistance in prostate cancer (PCa) are needed. Prostate cancer sphere-forming cells (PCSCs) (also termed prostate cancer stem-like cells) likely participate in tumor progression and recurrence, and they are important therapeutic targets. We established PCSC-enriched spheres by culturing human (DU145) and murine (TRAMP-C2) PCa cells in growth factor-defined serum-free medium, and we characterized stem-like properties of clonogenicity and tumorigenicity. The efficacy of two different oncolytic herpes simplex viruses (oHSVs) (G47Δ and MG18L) in PCSCs was tested alone and in combination with radiation; chemotherapy; and inhibitors of phosphoinositide 3-kinase (PI3K), Wnt, and NOTCH in vitro; and, G47Δ was tested with the PI3K inhibitor BKM120 in a PCSC-derived tumor model in vivo. PCSCs were more tumorigenic than serum-cultured parental cells. Human and murine PCSCs were sensitive to oHSV and BKM120 killing in vitro, while the combination was synergistic. oHSV combined with radiation, docetaxel, Wnt, or NOTCH inhibitors was not. In athymic mice bearing DU145 PCSC-derived tumors, the combination of intra-tumoral G47Δ and systemic BKM120 induced complete regression of tumors in 2 of 7 animals, and it exhibited superior anti-tumor activity compared to either monotherapy alone, with no detectable toxicity. oHSV synergizes with BKM120 in killing PCSCs in vitro, and the combination markedly inhibits tumor growth, even inducing regression in vivo." @default.
W2928533142 created "2019-04-11" @default.
W2928533142 creator A5006633218 @default.
W2928533142 creator A5035209845 @default.
W2928533142 creator A5038096872 @default.
W2928533142 creator A5052321786 @default.
W2928533142 creator A5059949459 @default.
W2928533142 creator A5065492142 @default.
W2928533142 creator A5073216396 @default.
W2928533142 creator A5084563024 @default.
W2928533142 date "2019-06-01" @default.
W2928533142 modified "2023-10-14" @default.
W2928533142 title "Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells" @default.
W2928533142 cites W1541370161 @default.
W2928533142 cites W1974763195 @default.
W2928533142 cites W1997203401 @default.
W2928533142 cites W2025581009 @default.
W2928533142 cites W2026234789 @default.
W2928533142 cites W2034881941 @default.
W2928533142 cites W2048120311 @default.
W2928533142 cites W2058531798 @default.
W2928533142 cites W2087183910 @default.
W2928533142 cites W2099961846 @default.
W2928533142 cites W2100032290 @default.
W2928533142 cites W2109517496 @default.
W2928533142 cites W2118312408 @default.
W2928533142 cites W2119333435 @default.
W2928533142 cites W2128450583 @default.
W2928533142 cites W2141417189 @default.
W2928533142 cites W2141540918 @default.
W2928533142 cites W2142072987 @default.
W2928533142 cites W2153382986 @default.
W2928533142 cites W2154871907 @default.
W2928533142 cites W2165652424 @default.
W2928533142 cites W2170200594 @default.
W2928533142 cites W2597432644 @default.
W2928533142 cites W2597893733 @default.
W2928533142 cites W2613524609 @default.
W2928533142 cites W2626176884 @default.
W2928533142 cites W2763367287 @default.
W2928533142 cites W2794336625 @default.
W2928533142 cites W2889646458 @default.
W2928533142 cites W4211087830 @default.
W2928533142 doi "https://doi.org/10.1016/j.omto.2019.03.008" @default.
W2928533142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6468160" @default.
W2928533142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31016228" @default.
W2928533142 hasPublicationYear "2019" @default.
W2928533142 type Work @default.
W2928533142 sameAs 2928533142 @default.
W2928533142 citedByCount "20" @default.
W2928533142 countsByYear W29285331422019 @default.
W2928533142 countsByYear W29285331422020 @default.
W2928533142 countsByYear W29285331422021 @default.
W2928533142 countsByYear W29285331422022 @default.
W2928533142 countsByYear W29285331422023 @default.
W2928533142 crossrefType "journal-article" @default.
W2928533142 hasAuthorship W2928533142A5006633218 @default.
W2928533142 hasAuthorship W2928533142A5035209845 @default.
W2928533142 hasAuthorship W2928533142A5038096872 @default.
W2928533142 hasAuthorship W2928533142A5052321786 @default.
W2928533142 hasAuthorship W2928533142A5059949459 @default.
W2928533142 hasAuthorship W2928533142A5065492142 @default.
W2928533142 hasAuthorship W2928533142A5073216396 @default.
W2928533142 hasAuthorship W2928533142A5084563024 @default.
W2928533142 hasBestOaLocation W29285331421 @default.
W2928533142 hasConcept C121608353 @default.
W2928533142 hasConcept C126322002 @default.
W2928533142 hasConcept C203014093 @default.
W2928533142 hasConcept C2776438761 @default.
W2928533142 hasConcept C2779723316 @default.
W2928533142 hasConcept C2780192828 @default.
W2928533142 hasConcept C28328180 @default.
W2928533142 hasConcept C502942594 @default.
W2928533142 hasConcept C54355233 @default.
W2928533142 hasConcept C55427017 @default.
W2928533142 hasConcept C71924100 @default.
W2928533142 hasConcept C82210918 @default.
W2928533142 hasConcept C86803240 @default.
W2928533142 hasConcept C96232424 @default.
W2928533142 hasConceptScore W2928533142C121608353 @default.
W2928533142 hasConceptScore W2928533142C126322002 @default.
W2928533142 hasConceptScore W2928533142C203014093 @default.
W2928533142 hasConceptScore W2928533142C2776438761 @default.
W2928533142 hasConceptScore W2928533142C2779723316 @default.
W2928533142 hasConceptScore W2928533142C2780192828 @default.
W2928533142 hasConceptScore W2928533142C28328180 @default.
W2928533142 hasConceptScore W2928533142C502942594 @default.
W2928533142 hasConceptScore W2928533142C54355233 @default.
W2928533142 hasConceptScore W2928533142C55427017 @default.
W2928533142 hasConceptScore W2928533142C71924100 @default.
W2928533142 hasConceptScore W2928533142C82210918 @default.
W2928533142 hasConceptScore W2928533142C86803240 @default.
W2928533142 hasConceptScore W2928533142C96232424 @default.
W2928533142 hasFunder F4320332161 @default.
W2928533142 hasLocation W29285331421 @default.
W2928533142 hasLocation W29285331422 @default.
W2928533142 hasLocation W29285331423 @default.
W2928533142 hasLocation W29285331424 @default.